DRUG NAME: Amoxicillin (Amoxycillin)

---

---

Therapeutic Class: Antibiotic

---

Subclass: Aminopenicillin (Beta-Lactam — Penicillinase-Susceptible)

• Natural penicillins (benzylpenicillin, phenoxymethylpenicillin) — narrower spectrum, no gram-negative coverage
• Penicillinase-resistant penicillins (cloxacillin, flucloxacillin) — anti-staphylococcal, no gram-negative coverage
• Aminopenicillin + beta-lactamase inhibitor combinations (amoxicillin-clavulanate) — broader spectrum due to beta-lactamase inhibitor component → covered in separate monograph
• Extended-spectrum penicillins (piperacillin) — anti-pseudomonal activity
• Ampicillin — identical spectrum but inferior oral bioavailability; largely replaced by amoxicillin for oral use

---

Schedule (India):

---

Route(s):

• Oral (capsules — swallowed whole; tablets — swallowed whole or chewed [dispersible tablets]; oral suspension/dry syrup — measured with graduated dosing device)
• IV (intravenous — limited availability as single-ingredient injection in India; amoxicillin-clavulanate IV is more widely stocked)
• IM (intramuscular — limited use; amoxicillin injection is not widely available as a single-ingredient IM formulation in India)

---

Biosimilar Status:

---

Formulations Available in India:

---

---

PHARMACOKINETICS

---

• For organisms with low MICs (GAS: MIC ~0.01 mcg/mL; S. pneumoniae [susceptible]: MIC ≤2 mcg/mL for non-meningeal infections): BD dosing (every 12 hours) achieves adequate fT>MIC. This is why 1 g BD or 500 mg BD dosing is effective for pharyngitis and uncomplicated pneumonia.
• For organisms with higher MICs (gram-negatives with MIC 4–8 mcg/mL, or intermediate-resistant pneumococcus): TDS dosing (every 8 hours) or high-dose BD (875 mg–1 g BD) is needed to maintain fT>MIC above the threshold.
• High-dose amoxicillin (80–90 mg/kg/day in children; 1 g TDS or 875 mg BD in adults) is specifically used to overcome penicillin-intermediate S. pneumoniae — the higher dose raises the fT>MIC above the revised CLSI non-meningeal susceptibility breakpoint of ≤2 mcg/mL.

---

---

---

ADULT INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

---

1. Amoxicillin is NOT effective against penicillinase-producing Staphylococcus aureus — which represents >90% of community S. aureus isolates in India. For suspected staphylococcal infections (purulent cellulitis, abscess, wound infection), use cloxacillin or amoxicillin-clavulanate instead.
2. Amoxicillin alone vs amoxicillin-clavulanate: For many common community infections in India (GAS pharyngitis, uncomplicated pneumonia, H. pylori eradication, uncomplicated cystitis with susceptible organism), amoxicillin alone is sufficient. Adding clavulanic acid unnecessarily increases GI side effects (particularly diarrhoea), broadens spectrum, increases cost, and contributes to resistance. Reserve amoxicillin-clavulanate for infections where beta-lactamase-producing organisms are likely (animal bites, chronic sinusitis, recurrent AOM, aspiration pneumonia, complicated UTI, diabetic foot infections).
3. Rising resistance in India:E. coli resistance to amoxicillin in India is >60–70% (ICMR AMR data). Amoxicillin is therefore NOT recommended as empirical therapy for urinary tract infections in most Indian centres — use nitrofurantoin (for uncomplicated cystitis) or a culture-guided approach. However, if culture confirms amoxicillin-susceptible E. coli, amoxicillin is an appropriate directed therapy (narrow spectrum — stewardship advantage).
4. Salmonella typhi resistance: Amoxicillin was historically first-line for enteric fever in India. Due to widespread resistance, amoxicillin is no longer recommended for empirical treatment of enteric fever — use ceftriaxone or azithromycin based on current ICMR/AIIMS protocols.
5. Duration matters: For many indications, shorter courses (5–7 days) are now evidence-based and equally effective as longer courses (10–14 days). However, for GAS pharyngitis (RF prevention), the 10-day course is NON-NEGOTIABLE — shorter courses do not reliably eradicate GAS and do not prevent RF.

---

Primary Indications (Approved / Standard in India)

---

1. When to prefer this drug over alternatives:
   • Preferred over phenoxymethylpenicillin for most patients in Indian practice because: (a) better oral bioavailability (~80–90% vs ~60%); (b) NO food restriction (can take with meals — simpler for patients); © excellent palatability of paediatric suspension (strawberry/banana flavoured — much better accepted by children than bitter penicillin V suspension); (d) simpler dosing (BD vs QID); (e) wider availability in Indian pharmacies.
   • Phenoxymethylpenicillin retains a niche advantage in antimicrobial stewardship (narrower spectrum — no gram-negative coverage), but this advantage is clinically marginal for an infection caused by GAS (which is exquisitely susceptible to both drugs).
   • ℹ️ Single-dose IM benzathine penicillin (1.2 MU for adults; 600,000 IU for children <27 kg) remains an alternative when compliance with a 10-day oral course is uncertain.
2. When NOT to use:
   • ⛔ Penicillin allergy (IgE-mediated) — use azithromycin (500 mg OD × 5 days) or clarithromycin (250 mg BD × 10 days). For non-anaphylactic penicillin allergy: cephalexin (500 mg BD × 10 days) may be used.
   • ⚠️ Do NOT prescribe for viral pharyngitis — antibiotics provide no benefit and drive resistance. Use Centor/McIsaac scoring (≥3 criteria) or RADT for GAS to guide prescribing.
   • ⚠️ Do NOT use amoxicillin in patients with suspected infectious mononucleosis (EBV infection) — aminopenicillins (amoxicillin, ampicillin) cause a characteristic maculopapular rash in ~70–100% of mononucleosis patients. This is NOT an IgE-mediated allergy — it is a virus-drug interaction (the mechanism involves polyclonal B-cell activation generating anti-aminopenicillin antibodies). ⚠️ This rash does NOT predict future penicillin allergy and should NOT be documented as “penicillin allergy.” However, it can be extensive and distressing. If pharyngitis may be due to EBV: check heterophile antibody (monospot test) or send EBV serology before prescribing amoxicillin. If EBV is confirmed, use supportive care (no antibiotic needed) or, if bacterial superinfection is suspected, use a non-aminopenicillin antibiotic (azithromycin, cephalexin).
   • ⚠️ Do NOT use for peritonsillar abscess (requires drainage + IV antibiotics).
3. NLEM India status: ✅ Listed in NLEM India 2022 — Section 6.2 (Antibacterials — Beta-lactam medicines). Capsules 250 mg/500 mg, oral suspension 125 mg/5 mL, and dispersible tablets 250 mg are listed.
4. Time to response: Symptom improvement (reduced sore throat, defervescence) within 24–48 hours. If no improvement by 48–72 hours: reassess diagnosis (viral pharyngitis? peritonsillar abscess? mononucleosis? non-GAS bacterial cause?).
5. Treatment failure criteria:
   • Clinical failure: Persistent or worsening symptoms despite 48–72 hours of appropriate therapy with confirmed adherence.
   • Bacteriological failure: Positive throat culture for GAS after completing full 10-day course.
   • Recurrent GAS pharyngitis: ≥3 episodes in 6 months or ≥4 in 12 months → consider: (a) carrier state (asymptomatic GAS carriage with intercurrent viral pharyngitis — does NOT usually require treatment); (b) re-infection from household contacts; © co-pathogen producing beta-lactamase (switch to amoxicillin-clavulanate 875/125 mg BD × 10 days or clindamycin 300 mg TDS × 10 days); (d) IM benzathine penicillin (single dose — guarantees eradication).
6. Mandatory baseline investigations: Not mandatory for empirical treatment based on clinical criteria (Centor/McIsaac ≥3). RADT or throat culture recommended where available.
7. Specialist initiation:Not required. PHC/CHC-level prescribing is appropriate. Any registered medical practitioner can prescribe.
8. Indian guideline source: IAP Guidelines on Acute Pharyngitis and RF Prevention (2017); API Textbook of Medicine (current edition); ICMR Guidelines on RF/RHD Prevention; WHO RF Prevention Guidelines.
9. Key safety warning: ⚠️ EBV-associated aminopenicillin rash — see point 2 above. In a young adult with pharyngitis, tonsillar enlargement, cervical lymphadenopathy, and fatigue: consider mononucleosis before prescribing amoxicillin. Check monospot or EBV serology. ⚠️ Complete the 10-day course — premature discontinuation is the most common reason for failure of RF prevention in India.
10. Dose adjustment: No renal/hepatic adjustment needed for a 10-day course at standard doses in patients with normal organ function. For severe CKD (eGFR <30): reduce to 250 mg BD and extend interval.

---

• If atypical pneumonia is clinically suspected (dry cough, interstitial infiltrates on X-ray, young adult, outbreaks, exposure history for Legionella or Mycoplasma) or if the patient has risk factors for dual typical + atypical infection: add azithromycin 500 mg OD × 3–5 days or doxycycline 100 mg BD × 5–7 days to amoxicillin.
• Amoxicillin alone does NOT cover Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella pneumophila.
• API Textbook recommends amoxicillin ± macrolide for mild CAP based on clinical judgement regarding atypical pathogen likelihood.

1. When to prefer over alternatives:
   • Amoxicillin is the narrowest effective spectrum oral antibiotic for pneumococcal CAP — preferred over amoxicillin-clavulanate, fluoroquinolones, or cephalosporins for mild outpatient CAP as an antimicrobial stewardship principle.
   • Preferred over azithromycin monotherapy for CAP in India because: (a) pneumococcal azithromycin resistance is rising in India (~10–20% in some regions per ICMR AMR data); (b) amoxicillin reliably kills pneumococcus at achievable serum/tissue concentrations; © azithromycin does not cover pneumococcus as reliably as a beta-lactam.
   • ⚠️ Respiratory fluoroquinolones (levofloxacin, moxifloxacin) should be RESERVED for CAP treatment failure, penicillin allergy, or moderate-severe CAP — they are NOT first-line for mild outpatient CAP. Overuse of fluoroquinolones in India is a major antimicrobial stewardship concern and also masks underlying TB (both fluoroquinolones have anti-TB activity, leading to delayed TB diagnosis).
2. When NOT to use:
   • ⚠️ Moderate-severe CAP (CURB-65 ≥2, requiring hospitalisation) — amoxicillin alone is inadequate. Use IV ceftriaxone + azithromycin (or IV amoxicillin-clavulanate + azithromycin).
   • ⚠️ Aspiration pneumonia — polymicrobial including anaerobes → use amoxicillin-clavulanate (or clindamycin).
   • ⚠️ Hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) — different pathogen profile → not covered by amoxicillin.
   • ⚠️ Suspected TB — ⛔ Do NOT treat suspected pulmonary TB with amoxicillin. Amoxicillin may provide partial symptomatic improvement in TB (weak anti-mycobacterial activity + treatment of secondary bacterial infection) → delays TB diagnosis and promotes drug resistance. If TB is a differential: send sputum for AFB/GeneXpert before starting empirical antibiotics, or treat for TB (not for CAP).
3. NLEM status: ✅ Amoxicillin is NLEM-listed.
4. Time to response: Clinical improvement (reduced fever, improving cough, reduced dyspnoea) within 48–72 hours. If no improvement by 72 hours: reassess (chest X-ray, sputum culture, consider TB, consider broadening antibiotic coverage to amoxicillin-clavulanate or adding macrolide, consider hospitalisation if deteriorating).
5. Treatment failure criteria: Persistent fever >72 hours; worsening dyspnoea; new or spreading infiltrates on repeat CXR; haemodynamic instability. Action: hospitalise, obtain cultures (blood, sputum), switch to IV antibiotics (ceftriaxone + azithromycin).
6. Mandatory baseline investigations:
   • MANDATORY: Chest X-ray (PA view) — to confirm pneumonia and exclude TB, malignancy, effusion, abscess.
   • RECOMMENDED: SpO₂ (pulse oximetry — if <94% on room air, consider hospitalisation). CURB-65 scoring (Confusion, Urea >7 mmol/L, Respiratory rate ≥30, BP systolic <90 or diastolic ≤60, age ≥65). CBC, CRP (to guide severity and response). Sputum Gram stain and culture (where available). Sputum AFB/GeneXpert (if TB is a differential — MANDATORY in India where TB prevalence is high).
   • ⚠️ India-specific: In any patient with cough >2 weeks, weight loss, night sweats, or haemoptysis: rule out TB before diagnosing as CAP. This is a critical public health imperative.
7. Specialist initiation: Not required for mild outpatient CAP. PHC/CHC-level prescribing is appropriate. Refer if: no response by 72 hours, SpO₂ <94%, CURB-65 ≥2, suspected complications (effusion, abscess, empyema), or suspected TB.
8. Indian guideline source: API Textbook of Medicine (current edition) — chapter on Pneumonia; ICMR Treatment Guidelines for common infections; BTS CAP Guidelines (adapted for India); NICE Pneumonia Guidelines (2019 — endorsed shorter courses).
9. Key safety warning: ⚠️ Always consider TB in any Indian patient with pneumonia symptoms, especially if: cough >2 weeks, weight loss, haemoptysis, upper lobe infiltrate, cavitation, history of TB contact, HIV-positive. Amoxicillin is NOT a treatment for TB. Using amoxicillin for presumed “CAP” in a patient who actually has TB delays diagnosis by weeks and contributes to TB transmission.
10. Dose adjustment: For standard 5–7 day CAP course: reduce dose if eGFR <30 (see RENAL ADJUSTMENT). No hepatic adjustment needed.

---

1. When to prefer over alternatives: First-line for uncomplicated AOM. Preferred over amoxicillin-clavulanate for INITIAL therapy — reserve co-amoxiclav for treatment failure (persistent symptoms after 48–72 hours of amoxicillin), recurrent AOM, or patients who received amoxicillin within the past 30 days.
2. When NOT to use: AOM with TM perforation and purulent otorrhoea — add topical antibiotic drops (ciprofloxacin/ofloxacin otic). Chronic suppurative otitis media (CSOM) — different pathogen profile, requires ENT evaluation and typically topical therapy ± systemic antibiotics targeting Pseudomonas and anaerobes. Suspected mastoiditis — requires hospitalisation, IV antibiotics, and ENT consultation.
3. NLEM status: ✅ NLEM-listed.
4. Time to response: Improvement in ear pain and fever within 48–72 hours.
5. Treatment failure: Persistent symptoms after 48–72 hours → switch to amoxicillin-clavulanate (875/125 mg BD) OR cefuroxime axetil (500 mg BD). ENT referral for recurrent AOM (≥3 in 6 months or ≥4 in 12 months) — consider tympanostomy tubes.
6. Baseline investigations: Otoscopy (MANDATORY). No lab tests needed for uncomplicated AOM. Tympanometry if available.
7. Specialist initiation: Not required. PHC-level prescribing appropriate.
8. Indian source: IAP Guidelines on AOM Management; API Textbook of Medicine; ENT standard practice.
9. Safety warning: ⚠️ Do NOT miss mastoiditis — if postauricular swelling, tenderness, or forward displacement of the pinna is present, this is a surgical emergency requiring IV antibiotics and ENT referral. Do NOT treat with oral amoxicillin alone.
10. Dose adjustment: Standard adjustments apply.

---

• IDSA 2012 Guidelines recommend amoxicillin-clavulanate (not amoxicillin alone) as first-line for ABRS, citing the need for H. influenzae and M. catarrhalis coverage (both commonly produce beta-lactamase).
• Other guidelines (AAP, NICE, some Indian ENT practice) accept amoxicillin alone for uncomplicated, mild ABRS as initial therapy.
• Indian practice varies: Many Indian ENT specialists and GPs prescribe amoxicillin-clavulanate as first-line for sinusitis. Amoxicillin alone is acceptable for INITIAL therapy of mild ABRS; step up to amoxicillin-clavulanate if no response within 72 hours.

1. When to prefer: For initial empirical therapy of mild, uncomplicated ABRS without risk factors for resistance. Narrower spectrum than amoxicillin-clavulanate.
2. When NOT to use: Chronic rhinosinusitis (>12 weeks) — different pathogen profile, requires ENT evaluation. Complicated sinusitis (orbital cellulitis, frontal subperiosteal abscess, intracranial extension) — requires hospitalisation and IV antibiotics. Allergic/fungal sinusitis — antibiotics not indicated.
3. NLEM status: ✅ NLEM-listed.
4. Time to response: Improvement within 3–5 days. If no response by day 3–5: switch to amoxicillin-clavulanate or doxycycline; consider imaging (CT sinuses); consider ENT referral.
5. Indian source: API Textbook of Medicine; Indian ENT specialist practice; adapted from IDSA Sinusitis Guidelines (2012).
6. Safety warning: ⚠️ Distinguish bacterial from viral sinusitis before prescribing antibiotics. The vast majority of acute sinusitis episodes are viral and resolve spontaneously. Unnecessary antibiotic prescribing for viral sinusitis is a major AMR driver in India. Duration criteria (≥10 days without improvement), severity criteria, or “double sickening” should guide the decision to prescribe.

---

1. When to prefer amoxicillin-based regimens: Amoxicillin is used in virtually ALL H. pylori eradication regimens because of its consistently low resistance rate (<2%). It is the one constant across regimens — the choice between regimens depends on the partner drug (clarithromycin vs metronidazole vs levofloxacin) and local resistance patterns.
2. When NOT to use: ⛔ Penicillin allergy — use clarithromycin-based (without amoxicillin) or metronidazole-based quadruple therapy. Levofloxacin + PPI + bismuth + metronidazole is an amoxicillin-free rescue regimen.
3. NLEM status: ✅ Amoxicillin is NLEM-listed. PPIs (omeprazole, pantoprazole) are also NLEM-listed.
4. Time to response: Symptom improvement (dyspepsia, epigastric pain): 1–4 weeks after completing the eradication course. ⚠️ Confirm eradication with a non-invasive test (urea breath test or stool antigen test) at least 4 weeks after completing the antibiotic course AND at least 2 weeks after stopping PPI. Testing too early or while on PPI gives false negatives.
5. Treatment failure: If first-line triple therapy fails: use a different regimen that does NOT repeat the same antibiotics (e.g., if clarithromycin-based triple failed, use levofloxacin-based triple or bismuth quadruple). Do NOT simply repeat the same failed regimen.
6. Baseline investigations:
   • MANDATORY: Confirmed H. pylori diagnosis before treatment — by endoscopy (CLO test, histology), or non-invasive testing (urea breath test, stool antigen test, or serological testing). ⚠️ Do NOT prescribe empirical H. pylori eradication without confirmed diagnosis — this is inappropriate antibiotic use.
   • RECOMMENDED: Upper GI endoscopy for patients with alarm features (age >45 with new-onset dyspepsia, weight loss, dysphagia, GI bleeding, anaemia, persistent vomiting).
7. Specialist initiation: Not required for confirmed uncomplicated H. pylori infection treated with standard first-line regimen. Gastroenterology referral for: treatment failure, recurrent infection, complicated peptic ulcer disease, MALT lymphoma.
8. Indian source: API Textbook of Medicine — chapter on Peptic Ulcer Disease and H. pylori; Indian Society of Gastroenterology (ISG) guidelines on H. pylori management; Maastricht VI / Florence Consensus adapted for India.
9. Safety warning: ⚠️ Antibiotic resistance in India is the primary reason for H. pylori treatment failure. Clarithromycin resistance (~15–30%) and metronidazole resistance (~80–90%) are both high in India. Despite this, metronidazole-based regimens can still work at higher doses (500 mg TDS–QID) for partial resistance. Culture and susceptibility testing (limited availability in India) should be considered after second-line failure.
10. Dose adjustment: Standard renal adjustment applies for amoxicillin component (reduce if eGFR <30). No hepatic adjustment.

---

1. When to prefer: ONLY when culture confirms amoxicillin-susceptible organism. Narrower spectrum than fluoroquinolones or cephalosporins — stewardship advantage. Preferred for susceptible Enterococcus faecalis UTI (enterococci are intrinsically resistant to cephalosporins — amoxicillin or ampicillin are the drugs of choice for susceptible enterococcal UTI).
2. When NOT to use: ⛔ NEVER use empirically for UTI in India — resistance rates are too high. ⛔ NOT effective against Klebsiella, Pseudomonas, or ESBL-producing organisms. ⛔ NOT effective for catheter-associated UTI (CAUTI) empirically.
3. NLEM status: ✅ NLEM-listed (amoxicillin). Nitrofurantoin is also NLEM-listed and is the preferred empirical first-line for uncomplicated cystitis.
4. Indian source: ICMR Treatment Guidelines for Antimicrobial Use; ICMR AMR Surveillance Data; API Textbook of Medicine.
5. Safety warning: ⚠️ AMR in India: Empirical use of amoxicillin for UTI in India will fail in >60% of cases due to E. coli amoxicillin resistance. This results in treatment failure, prolonged patient suffering, additional healthcare visits, and potential progression to pyelonephritis/sepsis. Prescribe empirical amoxicillin for UTI ONLY if culture/sensitivity testing is completely unavailable AND nitrofurantoin is also unavailable — and follow up with culture results to adjust therapy.

---

---

• Non-anaphylactic allergy: Cephalexin 2 g oral × 1 dose (30–60 min before procedure) — ⚠️ avoid if history of anaphylaxis to penicillin.
• Anaphylactic penicillin allergy: Azithromycin 500 mg oral × 1 dose (60 min before) OR Clindamycin 600 mg oral × 1 dose (30–60 min before).

1. Who receives prophylaxis (high-risk indications): (a) Prosthetic heart valves (mechanical or bioprosthetic); (b) Previous infective endocarditis; © Unrepaired cyanotic congenital heart disease; (d) Repaired CHD with residual defects at or adjacent to prosthetic material; (e) Cardiac transplant recipients with valvulopathy. ℹ️ Indian practice extension: Many Indian centres also provide prophylaxis for patients with significant RHD (moderate-severe mitral/aortic regurgitation on echocardiography) — this is a practice-based decision, not strictly evidence-based.
2. Which procedures require prophylaxis: Dental procedures involving gingival manipulation, periapical region, or perforation of oral mucosa (tooth extraction, periodontal procedures, implant placement, scaling with anticipated bleeding). NOT for: routine local anaesthesia injections through non-infected tissue, suture removal, dental X-rays, orthodontic bracket placement, or simple restorations above the gum line.
3. NLEM status: ✅ Amoxicillin is NLEM-listed.
4. Indian source: API Textbook of Medicine — IE chapter; AHA/ESC IE Guidelines adapted for India; AIIMS IE prophylaxis protocol.
5. Safety warning: ⚠️ Do NOT omit the pre-procedure dose and give it “after” the procedure — this is a common timing error. The antibiotic must be in the bloodstream BEFORE bacteraemia occurs (at the time of dental manipulation). Taking it after the procedure provides no prophylactic benefit.

---

---

Secondary Indications — Adults Only (Off-label)

---

---

---

---

---

• Pseudomonas has NOT been previously isolated from the patient’s sputum
• The exacerbation is mild-to-moderate (not requiring hospitalisation)
• A recent sputum culture (if available) shows amoxicillin-susceptible organisms
• The patient has NOT recently received amoxicillin (within the past 3 months — risk factor for resistance selection)

---

---

1. When to prefer amoxicillin ALONE over amoxicillin-clavulanate:
   • When recent sputum culture confirms amoxicillin-susceptible pathogen (e.g., non-beta-lactamase-producing H. influenzae, susceptible S. pneumoniae) — amoxicillin alone is narrower spectrum and avoids the increased diarrhoea from clavulanic acid (important because many bronchiectasis patients are chronically unwell and clavulanate-induced diarrhoea is particularly bothersome).
   • When the patient has a first or infrequent exacerbation without prior Pseudomonas isolation and without recent antibiotic exposure.
   • When antimicrobial stewardship is prioritised — amoxicillin alone is narrower spectrum.
2. When NOT to use amoxicillin alone (use amoxicillin-clavulanate or broader coverage instead):
   • ⚠️ Pseudomonas aeruginosa has been previously isolated from the patient’s sputum — even once. Once Pseudomonas colonises bronchiectatic airways, it tends to persist and is the likely pathogen in subsequent exacerbations. Use oral ciprofloxacin 500–750 mg BD × 14 days (first-line for Pseudomonal bronchiectasis exacerbation) or IV anti-pseudomonal antibiotics if severe (piperacillin-tazobactam, ceftazidime, meropenem — with or without IV aminoglycoside). ⛔ Amoxicillin (with or without clavulanate) has NO activity against Pseudomonas.
   • ⚠️ Recent amoxicillin use (within the past 3 months) — risk of selection of beta-lactamase-producing H. influenzae → use amoxicillin-clavulanate instead.
   • ⚠️ Frequent exacerbations (≥3 per year) — these patients often have more resistant organisms → sputum culture-guided therapy is essential. Empirically, amoxicillin-clavulanate or doxycycline is more appropriate than amoxicillin alone.
   • ⚠️ Severe exacerbation requiring hospitalisation — needs IV antibiotics (amoxicillin-clavulanate IV, or ceftriaxone, or anti-pseudomonal agents if Pseudomonas is suspected).
   • ⚠️ Patient with known ABPA (allergic bronchopulmonary aspergillosis) — exacerbation may be fungal, not bacterial. Check IgE levels, eosinophil count, consider itraconazole. Do NOT treat all exacerbations with antibiotics reflexively.
   • ⚠️ Haemoptysis — if moderate-to-severe haemoptysis is the presenting feature of the exacerbation, the priority is haemoptysis management (bronchial artery embolisation if massive; CT angiography), not just antibiotics.
3. NLEM India status: ✅ Amoxicillin is NLEM-listed. However, no specific NLEM indication listing for bronchiectasis — the NLEM lists amoxicillin for “infections.”
4. Time to response: Reduction in sputum purulence and volume within 3–5 days. Defervescence (if febrile) within 48–72 hours. If no improvement by 5–7 days: reassess — repeat sputum culture, consider broadening coverage (amoxicillin-clavulanate, doxycycline, or fluoroquinolone), consider CT chest (rule out mycobacterial superinfection, abscess, aspergilloma).
5. Treatment failure criteria:
   • No improvement in sputum purulence/volume by day 5–7.
   • Worsening dyspnoea, new fever, or new CXR infiltrates during treatment.
   • Early relapse within 2 weeks of completing the antibiotic course.
   • Action: Obtain sputum culture (including AFB smear/GeneXpert — TB reactivation in post-TB bronchiectasis is common in India). Broaden antibiotic coverage based on culture results. Pulmonology referral if not already involved.
6. Mandatory baseline investigations:
   • MANDATORY: Sputum culture and sensitivity (⚠️ BEFORE starting antibiotics) — this is more important in bronchiectasis than in CAP because: (a) recurrent infections require targeted therapy; (b) Pseudomonas isolation changes management completely; © resistance patterns vary between patients based on prior antibiotic exposure. Indian pulmonologists should maintain a “sputum culture history” for each bronchiectasis patient — documenting all previous isolates. This guides empirical therapy for future exacerbations.
   • MANDATORY: Chest X-ray (PA view) — to assess for new infiltrates, effusion, abscess, or underlying TB reactivation.
   • RECOMMENDED: SpO₂ (pulse oximetry). CBC, CRP (severity and response assessment). Sputum AFB smear/GeneXpert (⚠️ CRITICAL in India — reactivation of TB in post-tubercular bronchiectatic lungs is common; “purulent exacerbation” may actually be TB relapse).
   • RECOMMENDED (for baseline/initial evaluation — if not previously done): HRCT chest (gold standard for bronchiectasis diagnosis and extent assessment); sputum for fungal culture (ABPA); serum IgE and eosinophil count (ABPA); immunoglobulin levels (if immunodeficiency suspected); sweat chloride test (if cystic fibrosis suspected — rare in Indian adults but possible).
7. Specialist initiation: ⚠️ Recommended — bronchiectasis management (including acute exacerbation) should ideally involve a pulmonologist. For a first or straightforward exacerbation in a patient with established bronchiectasis and a known susceptible pathogen, a general physician can initiate amoxicillin. But: (a) sputum culture should be sent before starting antibiotics; (b) the patient should have a pulmonologist involved in their long-term care; © escalation to specialist input if treatment failure, Pseudomonas isolation, frequent exacerbations, or diagnostic uncertainty.
8. Indian guideline source: API Textbook of Medicine (current edition) — chapter on Bronchiectasis; BTS Bronchiectasis Guideline (2019, adapted for Indian practice); ERS Bronchiectasis Guideline (2017); Indian Chest Society clinical practice statements. ℹ️ No specific ICMR guideline on bronchiectasis management exists — practice is primarily guided by API Textbook and adapted international guidelines.
9. Key disease-specific safety warning: ⚠️ Always consider TB reactivation in any Indian patient with bronchiectasis (especially post-TB bronchiectasis) presenting with “acute exacerbation.” Sputum AFB/GeneXpert should be sent with EVERY exacerbation in patients with post-TB bronchiectasis. Treating a TB relapse with amoxicillin alone will result in: (a) partial symptomatic improvement (amoxicillin has weak anti-mycobacterial activity + treats secondary bacterial infection); (b) delayed TB diagnosis; © ongoing TB transmission; (d) potential development of drug-resistant TB. ⚠️ This is the same concern as in CAP but is MAGNIFIED in bronchiectasis because the underlying structural lung damage from prior TB is the most common cause of bronchiectasis in India.
10. Common dose adjustment scenarios:
    • Renal impairment: Standard adjustments (see RENAL ADJUSTMENT — reduce dose/extend interval if eGFR <30).
    • Elderly patients with bronchiectasis: Common scenario in India. Standard dosing unless renal impairment requires adjustment. Monitor for GI side effects (diarrhoea in elderly can be debilitating).
    • Patients on long-term macrolide prophylaxis (azithromycin 250 mg 3 times/week): Many bronchiectasis patients with frequent exacerbations (≥3/year) are placed on long-term low-dose azithromycin for exacerbation reduction. When such patients develop an acute exacerbation, do NOT use azithromycin as the treatment antibiotic (already receiving it as prophylaxis → likely reduced efficacy). Use amoxicillin (or amoxicillin-clavulanate) for the acute exacerbation. Continue the azithromycin prophylaxis during the acute treatment course (some centres pause it; practice varies).

---

---

---

PAEDIATRIC DOSING (Specialist Only)

---

• Safety monitoring requirements specific to paediatric use:
  • Penicillin allergy assessment is MANDATORY before every new prescription — ask the parent/caregiver specifically about previous reactions to amoxicillin, augmentin (co-amoxiclav), or any other antibiotic.
  • ⚠️ Aminopenicillin rash in EBV infection: Children with infectious mononucleosis (EBV) who receive amoxicillin develop a characteristic widespread maculopapular rash in ~70–100% of cases. This is NOT an IgE-mediated allergy. Do NOT label the child as “penicillin-allergic” — document as “EBV-associated aminopenicillin rash — NOT allergic.” If pharyngitis in a child may be due to EBV (atypical features — significant hepatosplenomegaly, prominent fatigue, generalised lymphadenopathy, atypical lymphocytes on smear): consider monospot/EBV serology before prescribing amoxicillin.
  • Monitor for GI side effects (diarrhoea — common; nappy/diaper rash in infants secondary to diarrhoea).
  • ⚠️ Monitor adherence — especially for 10-day GAS pharyngitis courses. Parental counselling about course completion is critical in India where premature antibiotic discontinuation is extremely prevalent.
• Minimum age:
  • Amoxicillin can be used from birth (including preterm neonates) — see Neonatal Dosing below.
  • The oral suspension (125 mg/5 mL and 250 mg/5 mL) and dispersible tablets allow accurate dosing for all paediatric ages.
• Minimum weight: No strict minimum weight threshold — dosing is weight-based (mg/kg). Oral suspension and drops (100 mg/mL) allow accurate dosing for low-birth-weight and preterm infants.
• Formulation suitability for children:
  • Oral suspension / Dry syrup (125 mg/5 mL, 250 mg/5 mL): ✅ Excellent paediatric formulation. Widely available across India from multiple manufacturers. ✅ Palatability: Good to excellent — most Indian brands offer flavoured suspensions (strawberry, banana, orange, mango). Significantly better-tasting than phenoxymethylpenicillin, cloxacillin, or erythromycin suspensions. This is a major practical advantage for paediatric adherence. Measure with graduated oral syringe — NOT a household teaspoon.
  • Dispersible tablets (DT — 125 mg, 250 mg, 500 mg): ✅ WHO-preferred paediatric formulation. Can be dispersed in 5–10 mL of clean water to form a palatable suspension. Stable in tropical conditions (no cold-chain needed, no reconstitution shelf-life limitation). Increasingly available through NHM/government supply and Jan Aushadhi stores. ℹ️ Practical advantage over dry syrup: DTs do not require reconstitution, have longer shelf life, and are easier to transport and store in hot Indian conditions. Recommended by WHO for use in resource-limited settings.
  • Oral drops (100 mg/mL — paediatric concentrated drops): Suitable for infants where small volumes are needed. ⚠️ Concentration-verification is critical: 100 mg/mL (drops) ≠ 25 mg/mL (some syrup formulations). A 4-fold dosing error can occur if drops are confused with syrup. Always verify the concentration on the product label before calculating the dose volume.
  • Capsules (250 mg, 500 mg): Suitable for children ≥6 years who can swallow capsules whole. Do NOT open capsules and mix with food (no stability data; unpleasant taste of granules).
  • Tablets (250 mg, 500 mg, 875 mg): Suitable for older children/adolescents who can swallow tablets. Film-coated — swallow whole.
• Palatability: ✅ Amoxicillin suspension is one of the best-tolerated oral antibiotic formulations in paediatric practice in India. This is a significant advantage over: phenoxymethylpenicillin (bitter), cloxacillin (bitter), erythromycin (bitter/metallic), and clarithromycin (bitter). The good palatability contributes to better adherence and is one reason amoxicillin has largely replaced penicillin V for paediatric GAS pharyngitis in India.
• Age-specific pharmacokinetic differences:
  • Neonates (<28 days): Half-life prolonged (3–4 hours in term; 6–8 hours in preterm) due to immature renal tubular secretion. Requires extended dosing intervals (every 8–12 hours instead of every 8 hours). See Neonatal Dosing below.
  • Infants (1–6 months): Half-life approximately 2–3 hours. Standard weight-based dosing with every-8-hour frequency applies. Higher doses (up to 90 mg/kg/day) may be needed for AOM and pneumonia with suspected intermediate-resistant pneumococcus.
  • Children (>6 months to 12 years): Half-life approximately 1–1.5 hours (adult values). Clearance per kg is similar to adults. Weight-based dosing applies.
  • Adolescents (≥12 years or ≥40 kg): Transition to adult dosing (fixed-dose).

---

Neonatal Dosing (<28 days of life)

• Step-down from IV ampicillin after initial treatment of neonatal sepsis (when clinically improving and oral feeds are established)
• Outpatient treatment of possible serious bacterial infection (PSBI) in young infants when referral is not feasible — per WHO Simplified Antibiotic Regimen and MoHFW F-IMNCI guidelines (see below)
• UTI treatment in neonates (after initial parenteral therapy, for susceptible organisms)

---

---

---

Primary Indications — Paediatric (Approved / Standard in India)

---

1. When to prefer amoxicillin over penicillin V for GAS pharyngitis in children: ✅ Amoxicillin is preferred in most Indian paediatric settings because: (a) significantly better palatability of suspension (children accept it far more readily); (b) food-independent absorption (no need for empty-stomach dosing — much simpler for families); © simpler BD dosing; (d) wider availability in Indian pharmacies.
2. When NOT to use:
   • ⛔ Penicillin allergy — use azithromycin (12 mg/kg/day OD × 5 days, max 500 mg/day) or clarithromycin (15 mg/kg/day divided BD × 10 days).
   • ⚠️ Suspected mononucleosis (EBV): Do NOT prescribe amoxicillin until EBV is excluded (see General Notes above). If EBV is suspected: no antibiotic needed (viral infection); if bacterial superinfection of pharynx is suspected in EBV-positive patient, use azithromycin or cephalexin (non-aminopenicillin).
   • ⚠️ Do NOT prescribe for viral pharyngitis. In children <3 years, GAS pharyngitis is uncommon — most pharyngitis in this age group is viral. Antibiotics are rarely indicated for pharyngitis in children <3 years unless there is strong clinical evidence of GAS (household contact with confirmed GAS, scarlet fever-like rash, strawberry tongue).
   • ⚠️ Do NOT use shortened courses (<10 days) — incomplete RF prevention.
3. NLEM status: ✅ NLEM-listed (amoxicillin capsules, suspension, and dispersible tablets).
4. Time to response: Symptom improvement within 24–48 hours.
5. Treatment failure: Persistent symptoms after 48–72 hours despite confirmed adherence. Options: (a) repeat 10-day course with amoxicillin (compliance may have been the issue); (b) switch to amoxicillin-clavulanate (875/125 mg equivalent weight-based dose) × 10 days; © clindamycin 20 mg/kg/day divided TDS × 10 days; (d) single IM benzathine penicillin (guarantees eradication).
6. Specialist initiation: Not required. PHC/CHC-level prescribing is appropriate.
7. Indian source: IAP Guidelines on Acute Pharyngitis and RF Prevention (2017); IAP Textbook of Pediatrics (current edition); WHO RF Prevention Guidelines.
8. Safety warning: ⚠️ Complete the full 10-day course — counsel parents emphatically. Use a calendar/sticker chart to engage the child. Consider single-dose IM benzathine penicillin if adherence is genuinely doubtful.

---

A 15 kg child with bilateral AOM: High-dose amoxicillin 90 mg/kg/day.

• • Total daily dose = 15 × 90 = 1,350 mg/day
  • Divided BD = 675 mg per dose (~700 mg per dose — round to nearest practical volume)
  • Using 250 mg/5 mL suspension: 700 mg = 14 mL per dose → 14 mL BD
  • ℹ️ This is a LARGE volume for a child — may need to divide into 2 aliquots or consider using dispersible tablets if the child can manage them.

1. When to prefer: Amoxicillin is first-line for AOM. High-dose amoxicillin (80–90 mg/kg/day) is increasingly used as the DEFAULT dose for paediatric AOM in India rather than standard dose.
2. When NOT to use:
   • AOM treatment failure after 48–72 hours of amoxicillin → switch to amoxicillin-clavulanate (high dose: 90 mg/kg/day of amoxicillin component, divided BD) × 10 days, OR cefuroxime axetil (30 mg/kg/day divided BD × 10 days).
   • ⚠️ Penicillin allergy: Non-anaphylactic: cefuroxime axetil or cefdinir. Anaphylactic: azithromycin 10 mg/kg Day 1, then 5 mg/kg Days 2–5 (total 5 days), OR clindamycin 30 mg/kg/day divided TDS × 10 days.
   • AOM with mastoiditis → hospitalise + IV antibiotics + ENT consultation.
3. NLEM status: ✅ NLEM-listed.
4. Time to response: Improvement in ear pain and fever within 48–72 hours.
5. Treatment failure: Persistent or worsening symptoms at 48–72 hours → switch antibiotic (see above). If recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months) → ENT referral for consideration of tympanostomy tubes.
6. Indian source: IAP Guidelines on AOM Management; AAP/AAFP AOM Guideline (2013, adapted for India).
7. Safety warning: ⚠️ Diarrhoea is the most common adverse effect of high-dose amoxicillin in children (10–20%). Counsel parents: mild diarrhoea is expected and usually self-limiting. Maintain hydration. If diarrhoea is severe, bloody, or persistent: consider C. difficile (rare in children but possible) and review antibiotic. ⚠️ Nappy/diaper rash may worsen due to diarrhoea — barrier cream (zinc oxide) prophylactically during the antibiotic course.

---

---

---

---

---

Secondary Indications — Paediatric (Off-label)

---

---

---

---

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

---

---

---

---

---

• No withdrawal syndrome — can be stopped and restarted at any time.
• No rebound phenomenon — stopping simply allows the infection to persist or recur if treatment was incomplete.
• No re-titration needed — resume at the previous dose.
• Not a biologic — no immunogenicity concern.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

---

---

---

---

---

---

---

RENAL ADJUSTMENT

---

---

---

---

HEPATIC ADJUSTMENT

---

---

---

CONTRAINDICATIONS

---

---

---

1. Vague history (“I had a rash to Augmentin/Mox”): Clarify: (a) What was the reaction? (rash vs urticaria vs angioedema vs GI upset); (b) How soon after taking the drug? (within 1 hour → more likely IgE-mediated; after >72 hours → likely delayed non-IgE); © Was the patient also ill with a viral infection? (viral exanthem misattributed to drug); (d) Was it amoxicillin alone or amoxicillin-clavulanate? (cholestatic hepatitis from co-amoxiclav does NOT contraindicate amoxicillin alone).
2. Convincing IgE-mediated history: ⛔ Avoid ALL penicillins. Use alternatives appropriate to the indication.
3. EBV-associated rash to amoxicillin: ⚠️ This is NOT a penicillin allergy. Document carefully: “Aminopenicillin rash in the setting of EBV infection — NOT IgE-mediated penicillin allergy. Penicillins may be used in future.” This documentation protects the patient from lifelong inappropriate penicillin avoidance.
4. Penicillin allergy de-labelling: Formal penicillin skin testing (available at select Indian tertiary centres — AIIMS, PGI, CMC Vellore, select allergy clinics) can safely de-label >90% of patients who carry a false “penicillin allergy” label. Consider referral for testing when the patient has a critical need for penicillin (RF prophylaxis, syphilis in pregnancy, endocarditis).

---

CAUTIONS

---

---

---

PREGNANCY

---

---

---

---

LACTATION

---

---

---

---

ELDERLY

---

---

---

---

---

---

MAJOR DRUG INTERACTIONS

---

---

---

---

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

---

---

---

SERIOUS ADVERSE EFFECTS

---

---

---

---

MONITORING REQUIREMENTS

---

---

---

---

---

• Short treatment courses (5–14 days): Monitoring ends when the course is completed and the patient is clinically well. No post-course follow-up labs are needed (except: post-treatment throat culture for GAS pharyngitis in high-risk patients — optional; H. pylori eradication confirmation test at ≥4 weeks — recommended; UTI follow-up culture — recommended).
• Concurrent warfarin: Recheck INR 3–5 days after stopping amoxicillin to ensure return to baseline.
• Concurrent methotrexate: Check CBC 1 week after completing amoxicillin course.

---

PATIENT COUNSELLING

---

---

---

---

---

• Difficulty breathing, swelling of face/lips/tongue/throat, or a widespread bumpy/itchy rash (hives) — this could be a serious allergic reaction (RARE)
• Severe watery diarrhoea (more than 5 times a day) or bloody diarrhoea
• Severe skin rash with blistering, or mouth sores
• Yellowing of your eyes or skin (very rare with amoxicillin alone)
• Reduced urination or dark-coloured urine (very rare)"

---

---

• “Store capsules/tablets in the original pack in a cool, dry place below 30°C. Keep away from moisture.”
• “Liquid medicine (syrup): Keep in the fridge after mixing. If no fridge: keep in the coolest part of the house and use within 5 days. If kept in the fridge: use within 2 weeks. Throw away any leftover liquid after this.”
• “Dispersible tablets: Store at room temperature — no fridge needed.”
• “Keep all medicines away from children.”

---

• “For sore throat: Take for exactly 10 days — even if you feel completely well after 2–3 days. Stopping early can leave germs in your throat that may later harm your heart.”
• “For ear infection, chest infection, urine infection, skin infection: Take for the number of days your doctor has prescribed (usually 5–7 days). Complete the full course.”
• “For stomach germ (H. pylori): Take the full 14-day kit as prescribed. Take ALL the medicines in the kit, not just the amoxicillin.”

---

---

---

• Shake the bottle well before every dose — the medicine settles.
• Measure carefully with the syringe or cup — NOT a kitchen spoon.
• Complete all 10 days for sore throat — even if the child seems perfectly well.
• Watch for rash — if a mild rash appears after a few days, it is usually not serious, but tell the doctor. If the child develops facial swelling, difficulty breathing, or severe widespread rash: go to the hospital immediately.
• Diarrhoea is common — keep the child well hydrated with ORS. Use barrier cream (zinc oxide) on the nappy area to prevent rash.
• Store the liquid in the fridge — mark the bottle with the date you mixed it and throw it away after 14 days (or 5 days if no fridge)."

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

---

---

PRICE RANGE (INR)

---

---

---

---

CLINICAL PEARLS

---

---

VERSION

---

REFERENCES

---

1. CDSCO Product Insert — Mox (Amoxicillin) capsules 250 mg and 500 mg, Sun Pharma / Ranbaxy Laboratories. Approved indications, contraindications, dosing, and adverse effects. Also reviewed: Novamox (Cipla) product insert.
2. Indian Pharmacopoeia 2022 (IP 2022), Indian Pharmacopoeia Commission, Ghaziabad. 8th Edition. Monograph on Amoxicillin Trihydrate — specifications and official standards.
3. National List of Essential Medicines (NLEM) India 2022, Ministry of Health & Family Welfare, Government of India. Section 6.2 — Beta-lactam medicines: Amoxicillin capsules 250 mg/500 mg, oral suspension 125 mg/5 mL, dispersible tablets 250 mg are listed.
4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter 58: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. Amoxicillin pharmacology, PK/PD, spectrum, clinical uses.
5. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Chapters on: Pharyngitis; Pneumonia; Otitis Media; Sinusitis; Helicobacter pylori; UTI; Infective Endocarditis.
6. API Textbook of Medicine, 11th Edition (2019), Association of Physicians of India. Chapters on: Upper and Lower Respiratory Tract Infections; Pneumonia; Peptic Ulcer Disease and H. pylori; UTI; Rheumatic Fever.
7. IAP Guidelines on Acute Pharyngitis and RF Prevention (2017). Endorses amoxicillin 50 mg/kg/day BD × 10 days as first-line for GAS pharyngitis in children.
8. IAP Textbook of Pediatrics, 6th Edition (2021), Indian Academy of Pediatrics. Sections on: GAS pharyngitis, AOM, pneumonia, UTI, neonatal sepsis.
9. AAP/AAFP Clinical Practice Guideline: The Diagnosis and Management of Acute Otitis Media (2013). Lieberthal AS et al., Pediatrics 2013;131:e964–e999. High-dose amoxicillin (80–90 mg/kg/day) recommendation.
10. WHO Pocket Book of Hospital Care for Children (Indian Adaptation), MoHFW. Amoxicillin dosing for paediatric pneumonia.
11. MoHFW F-IMNCI Guidelines. WHO Simplified Antibiotic Regimen for PSBI in young infants (amoxicillin 50 mg/kg/dose oral BD + gentamicin IM).
12. WHO Recommendations on Newborn Health (2017). Community-based management of PSBI with simplified antibiotic regimens.
13. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes. Referenced for empirical antibiotic guidance in Indian practice; AMR resistance data for E. coli, S. pneumoniae, and H. influenzae in India.
14. ICMR AMR Surveillance Data (Annual Reports). Referenced for E. coli amoxicillin resistance rates (>60–70%), pneumococcal penicillin resistance data, and H. pylori clarithromycin resistance data in India.
15. ISG (Indian Society of Gastroenterology) Guidelines on H. pylori Management. Referenced for triple therapy, quadruple therapy, and sequential therapy recommendations.
16. Maastricht VI / Florence Consensus Report on H. pylori Management (2022). Adapted for Indian practice — 14-day treatment duration, concomitant therapy.
17. BTS CAP Guidelines / NICE Pneumonia Guidelines (2019). Referenced for 5-day course evidence and amoxicillin as first-line for mild CAP.
18. BTS Bronchiectasis Guideline (2019) / ERS Bronchiectasis Guideline (2017). Referenced for bronchiectasis exacerbation treatment duration (14 days) and pathogen-specific guidance.
19. GOLD (Global Initiative for Chronic Obstructive Lung Disease) Report. Referenced for COPD exacerbation antibiotic criteria (Anthonisen classification).
20. IDSA Sinusitis Guidelines (2012). Referenced for ABRS antibiotic recommendations.
21. AHA IE Prevention Guidelines (2007, reaffirmed). Referenced for endocarditis prophylaxis — amoxicillin 2 g oral single dose.
22. FSRH UK Guideline on Drug Interactions with Hormonal Contraception (2019). Confirms no interaction between amoxicillin and combined OCPs. Referenced for OCP myth debunking.
23. NACO STI Treatment Guidelines. Referenced for chlamydia in pregnancy (amoxicillin as alternative).
24. PROPS Trial — Gaston et al., NEJM 1986. Referenced for SCD penicillin prophylaxis evidence (adapted for amoxicillin alternative use).
25. PATCH Trial — Thomas et al., NEJM 2013. Referenced for recurrent cellulitis prophylaxis (phenoxymethylpenicillin data — adapted context for amoxicillin comparisons).
26. NPPA (National Pharmaceutical Pricing Authority). DPCO ceiling prices for amoxicillin formulations.
27. PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana). Product catalogue — amoxicillin listed.
28. CDSCO website (https://cdsco.gov.in). Reviewed for banned FDC notifications and NSQ alerts.
29. PvPI (Pharmacovigilance Programme of India). ADR reporting methodology.
30. Nelson Textbook of Pediatrics, 21st Edition (2020). Chapter on Otitis Media — high-dose amoxicillin PK/PD rationale.

---